Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (August 2018)
21 slides from Corindus Vascular Robotics's investor presentation, Aug 7, 2018
Slide 1: Precision Vascular Robotics
Precision Vascular Robotics Corindus Vascular Robotics (CVRS) August 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward - looking statements” (as such term is defined in Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended), and information relating to the company, that are based on
Slide 3: Historical Overview of Corindus
3 Historical Overview of Corindus FDA Clears CorPath GRX 2 nd generation technology for use in PCI Company Goes Public trading on NYSE as CVRS FDA Clears CorPath 200 for use in PCI Mayo Telestenting Partnership established to explore remote treatment FDA Clears 1 st Automated Robotic Move (RoR) firs
Slide 4: Evolution of Corindus' Robot
• CorPath 200 cleared in 2012 • CorPath GRX cleared in late 2016 • ~2,000 robotic CorPath GRX cassettes sold globally PCI Evolution of Corindus’ Robot 4 1 CorPath Systems are not indicated for use in neuro interventions. • Steering committee established in 2018 NEURO 1 PERIPHERAL • CorPath GRX clear
Slide 5: Clinical Catalysts
Clinical Catalysts 5 Key Milestones for Clinical Development x Peripheral FDA clearance x RoR FDA clearance x Japan PMDA approval x CMO, Neuro Appointed x Neuro Steering Committee established x Remote 100+ mile case in porcine model Remote x Live remote PCI at TCT 2018 x First - in - human completed
Slide 6: Traditional vs Robotic Capabilities
Traditional vs Robotic Capabilities 6 Navigation Protection Methods Lesion Assessment Access to Care Redefining Coronary & Peripheral Interventions “Starting to see the best application for this technology is complex procedures. Easy stuff is just that; easy. But when wire position is critical and t
Slide 7: PCI & Peripheral Market Focus
PCI & Peripheral Market Focus 7 Targeting Subsets Where AI / Automation & Remote Capabilities Adds the Most Value Over 3M Procedures WW 1 (~900K US / ~2.2M OUS) PCI Over 2M Procedures WW 1 (~875K US / 1.3M OUS) PERIPHERAL 11% CLI (BTK) 2 1 Millennium Research Group. Reduced OUS market size to reflec
Slide 8: Adding Value in PCI & Peripheral Across Stakeholders
Adding Value in PCI & Peripheral Across Stakeholders 8 PHYSICIANS • 95% reduction in radiation exposure to physician 3 • Potential to conduct more complex procedures ( to be further aided by AI / automation capabilities ) • Increasing capabilities of average physicians to enable complex procedures •
Slide 9: Clinician Speaker Ryan Madder, M.D.
Clinician Speaker 9 Ryan Madder, M.D. FACC Spectrum Health Interventional Cardiologist Member of Cardiovascular Steering Committee Bio: Dr. Madder is a board - certified interventional cardiologist and is a Fellow of the American College of Cardiology. He earned his medical degree from University of
Slide 10: Remote Robotics Will Increase Access to Care
Remote Robotics Will Increase Access to Care • Global shortage of physicians , especially in neurovascular • Large portion of world’s population lives in rural/remote geographic area without access to adequate treatment • Increase access to care & address global physician shortage • Decrease time to
Slide 11: Remote Technology Development
11 Remote Technology Development Remote Porcine Test Case Conducted >100 Miles Away by Spectrum Healthcare Spectrum Healthcare Ludington Calvin College Grand Rapids Dr. Ryan Madder conducting first successful telestent procedure from Ludington, MI
Slide 12: Clinician Speaker Aquilla Turk, D.O.
Clinician Speaker 12 Aquilla "Quill" Turk, D.O. Medical University of South Carolina Director of Neurointerventional Surgery Associate Professor with a Joint Appointment in the Departments of Radiology and Neurosurgery Bio: Dr. Turk is involved in extensive research focusing on next generation devic
Slide 13: Stroke: A Serious and Costly Problem
Stroke: A Serious and Costly Problem 13 • Stroke ranks the #5 cause of death in the US (accounts for 1 in 19 deaths) 1 • > 7 million stroke survivors, two - thirds of which live with a moderate - to - severe disability 1 • Each passing minute during stroke results in the loss of ~2 million neurons .
Slide 14: Current Treatment Paradigm for Stroke
Current Treatment Paradigm for Stroke 14 Stroke is a Nascent Market Ischemic Stroke ~775K Large Vessel Occlusion ~335K Salvageable Tissue ~160K Patients Treated ~ 35K US Incidence 1 ~ 900K Strokes • Current ischemic stroke standard - of - care: - 3.0 - 4.5 hrs of Stroke Onset: tPA (IV) [clot dissolv
Slide 15: Remote Access Capabilities May Significantly Increase TAM
Remote Access Capabilities May Significantly Increase TAM 15 Ischemic Stroke ~775K Large Vessel Occlusion ~335K Salvageable Tissue ~160K Patients Treated ~35K US Incidence 1 ~900K Stroke • Time to treatment is key in the stroke market • Current treatment paradigm requires treatment within a 24 hour
Slide 16: Neurovascular Steering Committee / Milestones
Neurovascular Steering Committee / Milestones 16 Aquilla S. Turk, D.O. Medical University of South Carolina Ricardo A. Hanel , M.D. PhD Baptist Health System Tudor G. Jovin , M.D. University of Pittsburgh Medical Center J. Mocco , M.D. Mt. Sinai Hospital Vitor Mendes Pereria , M.D. Toronto Western H
Slide 17: Market Summary
~900K Stroke Incidence US 3 NEURO ~33% 4% Treated Market Summary 17 Over 3M Procedures WW 1 (~900K US / ~2.2M OUS) PCI Over 2M Procedures WW 1 (~875K US / ~1.3M OUS) PERIPHERAL 11% CLI (BTK) Target Market : Expand TAM with remote access Target Market : US (Complex) / OUS (Simple / Complex) Target Ma
Slide 18: Artificial Intelligence & Automation
Artificial Intelligence & Automation 18 • AI - Based Procedural Planning • Intra - Procedure Access to Decision Support Tools • Procedural Automation with Robotic Precision Our Vision for CorPath 1 Rao, et al. Impact of a Novel Advanced Robotic Wiring Algorithm on Time to Wire a Coronary Artery Bifu
Slide 19: Financials Snapshot
9 16 23 33 37 41 0 5 10 15 20 25 30 35 40 45 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Financials Snapshot 19 Revenue $ 0.8 M $ 2.3 M $ 2.4 M $ 4.2 M $ 1.5 M $ 1.7 M 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 ~Cash balance of $34.3M, Debt of $11.6M, 188.9M sh
Slide 20: Clinical Catalysts
Clinical Catalysts 20 Key Milestones for Clinical Development x Peripheral FDA clearance x RoR FDA clearance x Japan PMDA approval x Hired CMO, Neuro x Neuro Steering Committee established x Remote 100+ mile case in porcine model Remote x Live remote PCI at TCT 2018 x First - in - human completed by
Slide 21: Summary / Key Investment Thesis
Summary / Key Investment Thesis 21 • Significant progress in technology development and clinical expansion is creating a burning platform for hospitals to build a robotic program • AI / automation and remote access have the potential to add significant value to hospitals, patients, and doctors in th
Corindus Vascular Robotics — Investor Presentation (August 2018) on 6ix